Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer

Inclusion Criteria: * Willing and able to provide written informed consent and HIPAA authorization for the release of personal health information (HIPAA authorization will be included in the informed consent) * Males aged 18 years of age and above * Histological proof of adenocarcinoma of the prostate * Non-metastatic disease by computed tomography (CT), magnetic resonance imaging (MRI) or Nuclear medicine (NM) bone scan. Patients must have CT abdomen/pelvis with contrast prior to enrollment. * Metastatic disease may be permitted if NOT starting on any concomitant therapy (ie chemotherapy, anti-androgens) * Prior local therapy with prostatectomy or radiotherapy (including brachytherapy) or both * BMI \>30 kg/m2 with a concurrent obesity related comorbidity Obesity related comorbidity is defined as: * hypertension (resting blood pressure \>130/80 millimeters of mercury (mmHg) or being on medication to treat high blood pressure50), * coronary artery disease (defined as prior myocardial infarction, elevated coronary artery calcium score, positive stress test history), * dyslipidemia (triglyceride level of \>150mg/dL or being on medicine to treat high triglycerides; HDL \< 40mg/dL or being on medicine to treat cholesterol)51, * diabetes (fasting glucose \>126mg/dL, A1c \> 6.5% or on medication for diabetes)52, * pre-diabetes (fasting plasma glucose 100-125mg/dL)52, * elevated waist circumference (\>40 inches in men), * obstructive sleep apnea, * arthritis, or * non-alcoholic steatohepatitis. * Prior salvage or adjuvant radiation therapy is allowed but must have been completed at least 3 months prior to enrollment * Non-castrate levels of testosterone (\>50 ng/dL required) * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening * Vascular anatomy (including celiac, hepatic and gastric arteries) that in the opinion of the interventional radiologist is amenable to bariatric embolization as assessed on 3D CT angiography * Participants must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below: Hemoglobin ≥ 10.0 g/dL with no blood transfusion in the past 28 days Absolute neutrophil count (ANC) ≥ 1.0 x 109/L Platelet count ≥ 50 x 109/L Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) \< 2.5 x institutional upper limit of normal Estimated Glomerular filtration rate (GFR) \>60ml/min Exclusion Criteria: * Prior hormonal therapy within 12 months of enrollment * Planned concurrent cytotoxic chemotherapy or antiandrogens (ex. bicalutamide, abiraterone acetate, enzalutamide or any investigational agent). * Contraindication to the use of leuprolide, such as a previous hypersensitivity reaction to an Luteinizing hormone-releasing hormone (LHRH) analogue or any of the excipients in the leuprolide injection * Prior history of gastric, pancreatic, hepatic and/or splenic surgery * Prior radiation therapy to the upper abdomen (pelvic radiation is not an exclusion) * Prior embolization to the stomach, spleen or liver * Cirrhosis or known portal venous hypertension * Active peptic ulcer disease or significant risk factors for peptic ulcer disease including daily NSAID use or daily smoking * Hiatal hernia \>5cm in size * Active h.pylori infection (patients will be required to have negative h.pylori testing) * Weight \>400 pounds or BMI \>45kg/m2 * Known aortic arch pathology such as aneurysm or dissection * Major comorbidity that precludes procedure including significant cardiovascular disease or peripheral arterial disease including the following: Myocardial infarction within 6 months before screening Unstable angina within 3 months before screening New York Heart Association class III or IV congestive heart failure or a history of New York Heart Association class III or IV congestive heart failure unless a screening echocardiogram or multi-gated acquisition scan performed within 3 months before the randomization date demonstrates a left ventricular ejection fraction ≥ 45% History of clinically significant ventricular arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes) Uncontrolled hypertension as indicated by a minimum of 2 consecutive blood pressure measurements showing systolic blood pressure \> 170 mm Hg or diastolic blood pressure \> 105 mm Hg at screening Peripheral arterial stenting or bypass procedure within 6 months before screening Active claudication * Diabetes with A1c \>7% or requiring medication other than metformin * Known gastric motility dysfunction * Preexisting chronic abdominal pain * Positive stool occult study * Inflammatory bowel disease * Known history of allergy to iodinated contrast media * American Society of Anesthesiology (ASA) physical status classification system Class 4 of 5 (very high risk surgical candidates: class 4 = incapacitating disease that is a constant threat to life) at the time of screening for enrollment * Any condition in which the principle investigator feels participation in the trial would put the patient and undue risk